Recombinant human monoclonal antibody expressed in CHO binding to human Frizzled receptor. Vantictumab is a monoclonal antibody designed for the treatment of cancer.
Figure 1 WNT antagonists synergize with taxanes.
Vantictumab (VAN) has greater tumor growth inhibition when combined with nab-paclitaxel than gemcitabine. OMP-PN13 was treated with vantictumab (25 mg/kg) every 2 weeks and with gemcitabine (gem; 25 mg/kg) or nab-paclitaxel (nab-pac; 30 mg/kg) every week (n = 7 to 9 per group).
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.
Figure 2 Vantictumab (VAN) inhibits the tumor growth significantly.
OMP-PN25 was treated with vantictumab (25 mg/kg) every 2 weeks and with gemcitabine (20 mg/kg) or nab- paclitaxel (15 mg/kg) every week (n = 5 to 10 per group). mAb, monoclonal antibody.
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.
Figure 3 Administration of vantictumab or ipafricept 2 days before paclitaxel is essential for blocking tumor growth.
UM-PE13 treated with vantictumab (25 mg/kg) on day 1 or 4 with paclitaxel (pac; 20 mg/kg) given on day 1 or 4 in 3-week cycles (n = 6 to 8 per group).
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.
Figure 4 Sequential dosing of vantictumab and paclitaxel potentiates mitotic cell death in breast cancer.
OMP-B90 and UM-PE13 breast tumors respond to sequential vantictumab followed by paclitaxel. For OMP-B90, vantictumab (25 mg/kg) was administered on day 1 in 2-week cycles, for a total of six cycles. Paclitaxel (10 mg/kg) was given on day 1 or 3 in weekly cycles. For UM-PE13, vantictumab (25 mg/kg) was given on day 1 or 3, every other week, whereas paclitaxel (10 mg/kg) was given on day 3 every week.
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.
Figure 5 Sequential dosing of vantictumab and paclitaxel potentiates mitotic cell death in breast cancer.
Vantictumab promotes P21 induction and blockade of cyclin expression in OMP-B90.
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., ... & O’Young, G. (2017). WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death. Science advances, 3(6), e1700090.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-Frizzled Receptor ADCC Recombinant Antibody (Vantictumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human monoclonal antibody expressed in CHO binding to human Frizzled receptor. Vantictumab is a monoclonal antibody designed for the treatment of cancer.
CAT | Product Name | Application | Type |
---|---|---|---|
NAB-1026-sdAb | Recombinant Anti-Human Frizzled receptor VHH Single Domain Antibody | IP, FC, ChiP, Neut | Llama VHH |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-880 | Afuco™ Anti-Frizzled Receptor ADCC Recombinant Antibody (Vantictumab), ADCC Enhanced | Neut, ELISA, IF, IP, FuncS, FC | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-880. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.